Effective Initial Treatment for DLBCL
The Goal of RITUXAN Plus CHOP* Chemotherapy: Improve Survival Rates for Patients With DLBCL
RITUXAN plus CHOP chemotherapy is the most common treatment for DLBCL. Known as R-CHOP, this combination can significantly improve treatment results when compared with CHOP chemotherapy alone as an initial treatment for DLBCL.
In a large clinical study, RITUXAN plus CHOP chemotherapy was shown to significantly prolong survival in patients followed for up to 5 years. At 2 years, 69% of patients receiving RITUXAN plus CHOP chemotherapy were surviving versus 58% of those receiving CHOP chemotherapy alone. At 5 years, 58% of patients who received RITUXAN plus CHOP chemotherapy were surviving versus 46% of those who received CHOP chemotherapy alone. Remember that results may be different for different people. Read the Medication Guide for a summary of the most important information about RITUXAN. Be sure to ask your oncologist which treatment options are right for you.
RITUXAN plus CHOP chemotherapy was studied in the GELA LNH 98-5 trial, CHOP chemotherapy plus RITUXAN compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
This large study showed that for many patients with DLBCL, RITUXAN plus CHOP chemotherapy prolonged survival in patients followed up to 5 years after treatment. They were compared with patients who received CHOP chemotherapy alone.
RITUXAN was also studied in 2 other large clinical trials known as E4494 and MInT.
RITUXAN Is Right for Many Patients
RITUXAN has been shown to help many different kinds of patients. As an initial treatment for DLBCL, RITUXAN plus CHOP chemotherapy has been shown to:
- Benefit most patients with different stages of disease
- Significantly prolong survival in most elderly patients (60 years or older)
- Significantly prolong survival in most younger patients (59 years or younger)
RITUXAN® is indicated for the treatment of patients with previously untreated diffuse large B-cell, CD20-positive, NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
*CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone.
INDICATIONS
RITUXAN® (rituximab) is indicated for the treatment of patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
- Non-progressing (including stable disease), low-grade, CD20-positive B-cell NHL, as a single agent, after first-line CVP chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
IMPORTANT SAFETY INFORMATION
RITUXAN can cause serious side effects, some of which can be life-threatening, including: Progressive Multifocal Leukoencephalopathy (PML), infusion reactions, Tumor Lysis Syndrome (TLS), and severe skin reactions. Other serious and life-threatening side effects with RITUXAN include: hepatitis B virus reactivation, heart problems, infections, and stomach and bowel problems. Common side effects during RITUXAN infusions include: fever, headache, chills and shakes, nausea, itching, hives, cough, sneezing, and throat irritation or tightness.
Tell your doctor about any side effects that bother you or that do not go away. These are not all of the possible side effects with RITUXAN. Ask your doctor for more information.
Please read the Medication Guide in HTML or PDF versions for more information.
